The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

XEOMIN 100 units powder for solution for injection

Merz Pharmaceuticals GmbHPA1907/001/002

Main Information

Trade NameXEOMIN 100 units powder for solution for injection
Active SubstancesClostridium botulinum neuro-toxin type a (150 kd), free from complexing proteins
Dosage FormPowder for solution for injection
Licence HolderMerz Pharmaceuticals GmbH
Licence NumberPA1907/001/002

Group Information

ATC CodeM03AX01 botulinum toxin


License statusAuthorised
Licence Issued31/01/2014
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (See: Summary of Product Characteristics, section 4.2). Batches of human albumin in medicinal products marketed in Ireland shall be subject to control authority batch release in accordance with Article 114.2 of Directive 2001/83/EC as amended.
Marketing StatusMarketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back